Humacyte, Inc. (NASDAQ:HUMA) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 9.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,040,218 shares of the company’s stock after acquiring an additional 179,120 shares during the quarter. Geode Capital Management LLC’s holdings in Humacyte were worth $11,101,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. nVerses Capital LLC purchased a new stake in Humacyte in the second quarter valued at approximately $28,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Humacyte during the 3rd quarter valued at $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the 2nd quarter worth $83,000. FORA Capital LLC purchased a new position in shares of Humacyte in the 3rd quarter worth $96,000. Finally, Profund Advisors LLC purchased a new position in shares of Humacyte in the 2nd quarter worth $97,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Humacyte Trading Down 0.8 %

NASDAQ HUMA opened at $5.05 on Wednesday. The stock has a market cap of $635.59 million, a P/E ratio of -3.77 and a beta of 1.38. The company’s fifty day simple moving average is $4.76 and its 200-day simple moving average is $5.72. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97.

Analyst Upgrades and Downgrades

HUMA has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Friday, December 20th. TD Cowen reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Finally, BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.